YUCAIPA, Calif., Jan. 11, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading manufacturer of respiratory medical devices, recently announced it expects a sharp increase in demand for their Oxyview Nasal Cannulas in 2010 and beyond. The company points to the increasing prevalence of respiratory diseases, emerging hospital markets, and developing markets in Asia, Europe, Canada, Australia and Latin America.
Poor air quality, smoking, and even the Swine Flu have all contributed to an increase in the number of reported respiratory disease cases in the United States and worldwide. In turn, this means more patients are requiring oxygen support. While Ingen already has a strong presence in the market of home oxygen support patients, the company believes it can be successful targeting hospitals looking for convenient, reliable oxygen support systems.
In 2009, the Oxyview Nasal Cannulas garnered a lot of attention at several conventions throughout the world, including the MEDICA convention in Germany and the American Association of Respiratory Care (AARC) in San Antonio, Texas. Based on these and other positive showings, a significant number of distributors have showed interest in the Oxyview product line. Ingen hopes that this will help the company make its medical devices available worldwide, particularly in the developing markets of Asia, Europe, Canada, Australia and Latin America.
Oxyview Nasal Cannulas, and the recently introduced Oxyview Pulse Oximeter are touted as providing convenience because they're a better technology and they reduce the number of unnecessary service calls by providing additional assurance of oxygen flow. For those interested in learning more about these respiratory devices, Ingen's company website (www.Ingen-Tech.com) offers detailed information about the product, including specifications, printable brochures, and testimonials.
The company projects that the Oxyview Nasal Cannula will bring $10M in revenues, and the new Oxyview Pulse Oximeter an additional $1M in revenues in 2010.
For more information, please visit www.Ingen-Tech.com.
About Ingen:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.